Greg Kupp – President Life Sciences Division & Frank Tagliaferri – VP of Technical DevelopmentPace® Life Sciences were recently interviewed by Investment Reports. Read the full inter view here.
Pace ® is happy to share news from our client, ReveraGen BioPharma Inc., on a significant accomplishment! ReveraGen Completes NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy. Pace® Ann Arbor (legacy Velesco Pharmaceutical Services) contributed significantly to this success. Velesco Pharma (now Pace®) performed the drug product clinical formulation development and all drug
ReveraGen Completes NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy Read More »
Acquisition allows Pace® to provide full-service regulatory strategy and consulting services to advance FDA submissions across a wide range of therapeutic classes. Minneapolis, MN, September 1, 2022 – Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization (CDMO) and subsidiary of Pace®, ascience and technology company, announced today that it has acquired Biopharma
First Wave BioPharma Chooses Pace® Life Sciences as CDMO Partner. BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the selection of an enhanced enteric microgranule
Research involves microgranule delivery formulations for adrulipase BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that an abstract titled, “Formulation Development of Enterically Protected Spray Dried
Acquisition allows Pace® to provide regulatory and quality consulting services to support clients throughout the drug development process and improve commercial compliance in FDA-regulated environments. Minneapolis, MN, August 18, 2022 – Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization (CDMO) and subsidiary of Pace® Science and Technology Company, announced today that it
Company excels in Labor & Human Rights and Ethics performance for current Corporate Social Responsibility (CSR) Initiatives. Pace® Life Sciences, a division of Pace® Science and Technology Company, is pleased to announce that it has received a Bronze Award for its current state of sustainability. This award signifies that Pace® is in the top 50%
Pace® Life Sciences Awarded Bronze Medal from EcoVadis for Sustainability Efforts Read More »
Pharmaceutical Technology hosts “The Evolution of an NCE’s Suspension Formulation, from pre-GLP Studies to the Pharmacy Shelf” – a webinar presented by Dave Barnes, Ph.D., Vice President of Scientific Affairs for Pace® Life Sciences. To watch it live, tune in on Thursday, April 14 at 11 AM EDT. REGISTER HERE REGISTER HERE This presentation focuses
Frank Tagliaferri, Ph.D., Vice President of Pharmaceutical Development sat down with BioProcess International to discuss the growth the industry, and the growth of Pace® Life Sciences over the past few years. https://www.youtube.com/watch?v=t_w6Re3vZbU
Getting Drugs to Market – Dr Frank Tagliaferri, Pace Life Sciences Read More »
Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM Biocompare, The Buyer’s Guide for Life Sciences Published an Article: The Changing Landscape of Gene Therapy, written by Frank Tagliaferri, Ph.D., VP of Pharmaceutical Development & GM at Pace® Life Sciences (PLS). Read the full article
The Changing Landscape of Gene Therapy Read More »